Clinical Trial Search

Primary: Number of Participants Who Had Solicited Injection Site and Systemic Reactions After Vaccination With Fluzone 2007-2008 Formulation — 13; 4; 9; 2 Participants

Primary: Number of Participants With Solicited Local and Systemic Reactions After Vaccination With Fluzone® 2004-2005 Pediatric Formulation — 3; 7; 0; 2 Participants

Primary: Number of Participants Reporting Solicited Local and Systemic Reactions After Fluzone® Vaccination — 9; 6; 0; 2 Participants

Primary: The Percentage of Patients Achieving Target Sitting Blood Pressure of Less Than 130/85 — 34.0; 59.2 Percent of participants — p=0.0158

Primary: ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure — 1386; 1423…

Primary: Change in Low-density-lipoprotein Cholesterol (LDL-C) at 6 Weeks — -26.5; -11.9 percentage change — p=0.0000

Primary: Differences in Costs Between Two Revascularization Strategies for de Novo Coronary Lesions. — 5483; 7658.2 US dollars — p=<0.05

Primary: Number of Participants Who Are Clear/Almost Clear of Plaque Psoriasis From Baseline to End of Treatment Based on the Overall Disease Severity (ODS) Scale — 62; 44…

Primary: Asthma Control — 312; 72; 0; 229 Participants

Primary: Change From Baseline to End of Treatment (EOT) in Weekly Mean Pain Score on the Daily Pain Rating Scale (DPRS) — -3.8 scores on scale — p=< 0.0001

Primary: Cumulative Vasopressor Index (CVI) — 2.3; 3.0; -2.0; -1.4 units on a scale — p=0.238

Primary: Horizontal Action Halo Diameter at 28 Days — 1.0526; 1.0670 centimeter — p=0.832

Primary: LDL Cholesterol — 159.7; 157.8 mg/dl

Primary: Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS) 20. — 34; 37 patients — p=0.6031

Primary: Total Number of Oocytes — 12.4; 12.1 Number of oocytes